Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4285-4300

  O'Connor, Patrick M ^a   Jackman, Joany ^a   Bae, Insoo ^a   Myers, Timothy G ^a   Fan, Saijun ^a   Mutoh, Masato ^a   Scudiero, Dominic A ^b   Monks, Ann ^b   Sausville, Edward A ^b   Weinstein, John N ^a   Friend, Stephen ^c   Fornace Jr , Albert J ^a   Kohn, Kurt W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; PROTEIN P53;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; DNA SEQUENCE; DRUG POTENCY; GENE MUTATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, COMPLEMENTARY; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REFERENCE STANDARDS; RNA, MESSENGER; RNA, NEOPLASM; SACCHAROMYCES CEREVISIAE; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 0030865104     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M, Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
2. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
3. Grever, M. T., Schepartz, S. A., and Chabner, B. A. The National Cancer Institute Cancer Drug Discovery and Development Program. Semin. Oncol., 19: 622-638, 1992.
4. Boyd, M. R., and Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34: 91-95 1995.
5. Paull, K. D., Hamel, E., and Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: W. O. Foye (ed.) Cancer Chemotherapeutic Agents, pp. 9-45. Washington, DC, American Chemical Society, 1995.
6. Paull, K. D., Lin, C. M., Malspeis, L., and Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluate of differential cytotoxicity data. Cancer Res., 52: 3892-3900, 1992.
7. Cleaveland, E. S., Monks, A., Vaigro-Wolfe, A., Zaharevitz, D. W., Paull, K., Ardalan, K., Cooney, D. A., and Ford, H. J. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program. Biochem. Pharmacol., 49: 947-954, 1995.
8. Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., Monks, A. P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., and Paull, K. D. Neural computing in cancer drug development: predicting mechanism of action. Science (Washington DC), 258: 447-51, 1992.
9. Myers, T. G., Anderson, N. L., Waltham, M., Li, G., Buolawini, J. K., Scudiero, D. A., Paull, K. D., Sausville, E. A., and Weinstein, J. N. A protein expression database for the molecular pharmacology of cancer. Electrophoresis, 18: 647-653, 1997.
10. van Osdol, W. W., Myers, T. G., Paull, K. D., Kohn, K. W., and Weinstein, J. N. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl. Cancer Inst., 86: 1853-1859, 1994.
11. Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., and Fojo, T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest., 95: 2205-2214, 1995.
12. Wu, L., Smythe, A. M., Stinson, S. F., Mullendore, L. A., Monks, A., Scudiero, D. A., Paull, K. D., Koutsoukos, A. D., Rubinstein, L. V., Boyd, M. R., and Shoemaker, R. H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res., 52: 3029-3034, 1992.
13. Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., and Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46: 627-638, 1994.
14. Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R., and Scheper, R. J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer, 65: 230-237, 1996.
15. Koo, H-M., Monks, A., Mikheev, A., Rubinstein, L. V., Gray-Goodrich, M., McWilliams, M. J., Alvord, W. G., Oie, H. K., Gazdar, A. F., Paull, K. D., Zarbl, H., and Vande Woude, G. F. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors, in tumor cell lines harboring activated ras oncogenes. Cancer Res., 56: 5211-5216, 1996.
16. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-52, 1991.
17. Levine, A., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
18. Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res., 24: 141-146, 1996.
19. Fan, S., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
20. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
21. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
22. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-967, 1993.
23. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 1362: 847-849, 1993.
24. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
25. Hawkins, D. D., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
26. Fan, S., Chang, J., Smith, M. L., Duba, D., Fornace, A. J., Jr., O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
27. Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., and Brown, R. Cisplatin, camptothecin and paclitaxel sensitivities of cells with p53-associated multidrug resistance. Molecular Pharmacology. 50: 1536-1540, 1996.
28. Ishioka, C., Frebourg, T., Yan, Y. X., Vidal, M., Friend, S. H. Schmidt, S., and Iggo, R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet., 5: 124-129, 1993.
29. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science (Washington DC), 252: 1708-1711, 1991.
30. Jackman, J., Alamo, I., Jr., and Fornace, A. J., Jr. Genotoxic stress confers preferential and coordinate messenger RNA stability on the five GADD genes. Cancer Res., 54: 5656-5662, 1994.
31. Hollander, M. C., and Fornace, A. J., Jr. Induction of fos RNA by DNA-damaging agents. Cancer Res., 49: 1687-1692, 1989.
32. Freije, J. M. P., Lawrence J. A., Hollingshead, M. G., De La Rosa, A., Narayanan. V., Grever, M., Sausville, E. A., Paull, K., and Steeg, P. S. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nature Medicine, 3: 395-401, 1997.
33. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
34. Jayaraman, J., and Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029, 1995.
35. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81: 1013-1020, 1995.
36. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
37. Bae, I., Smith, M. L., Sheikh, M. S., Zhan, Q., Scudiero, D. A., Friend, S. H., O'Connor, P. M., and Fornace, A. J., Jr. An abnormality in the p53 pathway following gamma irradiation in many wild-type p53 human melanoma lines. Cancer Res., 56: 840-847, 1996.
38. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.
39. Bhatia, K., Goldschmidts, W., Gutierrez, M., Gaidano, G., Dalla-Favera, R., and Magrath, I. Hemi-or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J., 7: 951-956, 1993.
40. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Yokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
41. Kern, S. E., Redston, M., Seymour, A. B., Caldas, C. Powell, S. M., Kornacki, S., and Kinzler, K. W. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology. 107: 420-428, 1994.
42. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52: 4168-4174, 1992.
43. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-356, 1994.
44. 2-M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.